SCHEMBL29944141

SCHEMBL29944141

O=C(c1ccc(OC(F)F)cc1)N1CCCCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.65
ALDH1A1 P00352 7/20 0.65
HTT P42858 1/20 0.61
KDM4E B2RXH2 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
TSHR P16473 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
POLB P06746 1/20 0.54
MLYCD O95822 2/20 0.53
HSD17B10 Q99714 1/20 0.51
NPC1 O15118 1/20 0.51
MAPT P10636 1/20 0.51
RAB9A P51151 1/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29944014 0.84 KMT2A (0.68) HPGDALDH1A1HTTKDM4EL3MBTL1
SCHEMBL27479149 0.80 HPGD (1.00) HPGDALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL7132525 0.80 HPGD (1.00) HPGDALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL18088338 0.79 DRD2 (0.47) HPGDALDH1A1HTTKDM4EL3MBTL1
SCHEMBL5473172 0.79 HSD11B1 (0.55) ALDH1A1SMN1; SMN2MAPK1
SCHEMBL21926447 0.79 HSD11B1 (0.55) ALDH1A1SMN1; SMN2MAPK1
SCHEMBL5473170 0.79 HSD11B1 (0.55) ALDH1A1SMN1; SMN2MAPK1
SCHEMBL10721733 0.78 HPGD (0.95) HPGDALDH1A1KDM4EL3MBTL1MEN1
SCHEMBL2535533 0.78 HPGD (0.71) HPGDALDH1A1KDM4EL3MBTL1MEN1
SCHEMBL2535536 0.78 HPGD (0.96) HPGDALDH1A1HTTKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230110003-A1 PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) Valo Health, LLC 2023-04-13 US disclosed
US-11479564-B2 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) VALO HEALTH, INC. (US) 2022-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230110003-A1 PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) NAMPT, NAPRT, NNMT HPGD 105/4885ALDH1A1 265/4885HTT 791/4885
US-11479564-B2 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) NAMPT, NAPRT, NNMT HPGD 105/4885ALDH1A1 265/4885HTT 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.